For Doctors in a Hurry
- Clinicians lack data on how metacognitive therapy affects pediatric obsessive-compulsive disorder patients who also present with common comorbid psychiatric conditions.
- The researchers evaluated 37 patients aged 9 to 17 years who completed eight group therapy sessions and two parental workshops.
- Participants achieved a large reduction in symptoms with a Hedges’ g of 2.3 and an 81.1 percent response rate.
- The authors conclude that group metacognitive therapy is a feasible intervention even for pediatric patients with significant diagnostic comorbidities.
- Future research must determine if comorbid neurodevelopmental or anxiety disorders require modified treatment trajectories to improve patient response rates.
Pediatric obsessive-compulsive disorder remains a significant clinical challenge, often requiring a combination of pharmacotherapy and intensive behavioral interventions to achieve remission [1, 2]. While exposure-based protocols are the established first-line treatment, many youth in community settings present with complex comorbidities, such as autism or ADHD, which can complicate diagnosis and significantly hinder standard treatment response [3, 4]. Recent evidence suggests that addressing executive dysfunction (the cognitive processes required for goal-directed behavior) and maladaptive beliefs about thought processes may offer a necessary alternative for patients who do not respond to traditional approaches [5, 6, 7]. Metacognitive therapy, which targets the way patients think about and respond to their own internal cognitions, has emerged as an effective transdiagnostic framework for managing these underlying patterns across various emotional disorders [8, 9, 10]. A new study now evaluates how this metacognitive approach performs in a naturalistic pediatric population characterized by high rates of diagnostic complexity, where 53% of community-based patients would typically be excluded from traditional randomized controlled trials [4].
Protocol Design for Real-World Clinical Settings
The researchers conducted this study within a naturalistic clinical setting, a term referring to real-world community clinics where patient populations are not filtered by the strict exclusion criteria often found in controlled laboratory trials. This environment allowed for the inclusion of a diverse cohort of 37 participants aged 9 to 17 years, many of whom presented with the complex diagnostic profiles frequently encountered by practicing clinicians. By evaluating the intervention in a setting characterized by high rates of comorbidity, the study sought to determine if group metacognitive therapy is a feasible treatment for pediatric obsessive-compulsive disorder in real-world settings where patients often struggle with concurrent neurodevelopmental or anxiety-based conditions. This approach is particularly relevant for clinicians who find that the highly sanitized samples of major clinical trials do not reflect the diagnostic heterogeneity of their daily patient load.
The therapeutic intervention was delivered through a structured protocol consisting of eight sessions of group metacognitive therapy, which focuses on modifying how patients respond to intrusive thoughts rather than challenging the specific content of those thoughts. To reinforce these cognitive shifts and provide support for the family unit, the researchers also integrated two parental workshops into the treatment plan. Clinical progress was monitored through a comprehensive assessment framework; participants were diagnostically evaluated at pre-treatment and post-treatment to measure changes in symptom severity and diagnostic status. Furthermore, the youth completed self-report measures before, during, and after treatment, allowing the authors to track the trajectory of symptomatic and metacognitive change throughout the entire duration of the eight-week program. This longitudinal tracking provides a granular view of how cognitive shifts precede or accompany symptomatic relief.
Quantifying Symptom Reduction and Remission Rates
The primary analysis of the 37 participants revealed a substantial decline in obsessive-compulsive symptoms following the eight-week intervention. The researchers reported a significant reduction in OCD symptoms with an effect size of Hedges’ g = 2.3, a metric indicating a very large magnitude of change relative to the variability within the group. This robust statistical improvement translated into high levels of clinical success across the cohort. Specifically, the overall response rate for the total sample was 81.1%, defined as a meaningful reduction in symptom severity, while the overall remission rate for the total sample was 51.4%, signifying that more than half of the youth no longer met the diagnostic criteria for obsessive-compulsive disorder at the conclusion of the study. For the practicing physician, these figures suggest that metacognitive therapy may be a potent option even when delivered in a group format, which is often more resource-efficient than individual sessions.
Beyond the primary focus on obsessive-compulsive symptoms, the study tracked several secondary outcomes to assess the broader impact of the metacognitive approach. The data showed moderate to large improvements in comorbid symptoms, suggesting that the benefits of the therapy extended to the various neurodevelopmental and psychiatric conditions present in this complex patient population. Furthermore, the researchers observed moderate to large improvements in trait worry, which refers to a stable tendency to engage in anxious apprehension, as well as moderate to large improvements in metacognitive beliefs and strategies. These findings indicate that by targeting the underlying cognitive processes that maintain distress, such as how a child relates to their own thoughts, the intervention may address a transdiagnostic mechanism (a shared psychological process that contributes to multiple different disorders) that alleviates various forms of psychopathology simultaneously.
To understand how the intervention performed across different clinical profiles, the researchers explored three distinct diagnostic presentations within the study population: youth with OCD only, those with OCD and comorbid neurodevelopmental disorders, and those with OCD and comorbid anxiety disorders. While the overall cohort demonstrated high levels of improvement, the analysis revealed that the subgroups with comorbid disorders showed slightly lower response rates when compared to the group presenting with obsessive-compulsive disorder alone. This finding suggests that while metacognitive therapy remains effective in the presence of complex diagnostic profiles, the presence of additional neurodevelopmental or anxiety-related pathologies may influence the immediate clinical impact of the eight-session protocol, perhaps necessitating a longer course of treatment for these specific patients.
The study also identified unique patterns in how patients modified their underlying cognitive biases, specifically regarding thought-fusion beliefs. These beliefs represent a metacognitive conviction that thoughts can influence external events or are morally equivalent to actions (for example, the belief that thinking about a catastrophe makes it more likely to occur). The researchers found that the subgroups with comorbidities showed indications of delayed but steeper trajectories of change in thought-fusion beliefs throughout the course of treatment. Unlike the OCD-only group, which may have shown more linear progress, these complex patients appeared to require more time to engage with the metacognitive model before experiencing a rapid shift in their cognitive processing. This suggests that clinicians treating comorbid pediatric populations may need to account for a slower initial phase of cognitive restructuring followed by an accelerated period of symptomatic improvement, emphasizing the importance of clinical persistence during the early weeks of therapy.
References
1. Cohen SE, Boer AD, Storosum BWC, et al. Systematic Review and Meta-Analysis of Individual Participant Data: Randomized, Placebo-Controlled Trials of Selective Serotonin Reuptake Inhibitors for Pediatric Obsessive-Compulsive Disorder. Journal of the American Academy of Child & Adolescent Psychiatry. 2025. doi:10.1016/j.jaac.2025.01.001
2. Cuijpers P, Sijbrandij M, Koole SL, Andersson G, Beekman AT, Reynolds CF. Adding psychotherapy to antidepressant medication in depression and anxiety disorders: a meta-analysis. World Psychiatry. 2014. doi:10.1002/wps.20089
3. O’Loghlen J, McKenzie ML, Lang CP, Paynter J. Repetitive Behaviors in Autism and Obsessive-Compulsive Disorder: A Systematic Review. Journal of Autism and Developmental Disorders. 2024. doi:10.1007/s10803-024-06357-8
4. English AC, Brady M, Sanchez AL, Becker-Haimes E. How Many Anxious Kids in Community Mental Health Would Be Eligible for an RCT? And Does It Matter? Insights from a Naturalistic Sample and a Non-Systematic Review. Children. 2026. doi:10.3390/children13030413
5. Bakizadeh F, Mokhtari S, Saeed F, Mokhtari A, Koli PA, Shalbafan M. Cognitive Rehabilitation for Adult Patients With Obsessive-compulsive Disorder: A Systematic Review of Randomized Controlled Trials. Basic and Clinical Neuroscience Journal. 2024. doi:10.32598/bcn.2022.1604.3
6. Zargarinejad G, Mokhtari S, Mahdavi S, et al. Combining cognitive remediation and metacognitive therapy for improving cognitive functions and reducing symptoms severity of adult patients with obsessive-compulsive disorder in Tehran, Iran: study protocol for a randomized, controlled trial.. Trials. 2025. doi:10.1186/s13063-025-09219-5
7. Rajezi S, Ansari P, Yaghubi H, et al. Metacognitive Therapy Versus Cognitive Behavioral Therapy for OCD: A Randomized Controlled Trial. International journal of high risk behaviors and addiction. 2024. doi:10.5812/ijhrba-145235
8. Schaeuffele C, Meine LE, Schulz A, et al. A systematic review and meta-analysis of transdiagnostic cognitive behavioural therapies for emotional disorders. Nature Human Behaviour. 2024. doi:10.1038/s41562-023-01787-3
9. Philipp R, Kriston L, Lanio J, et al. Effectiveness of metacognitive interventions for mental disorders in adults—A systematic review and meta‐analysis (METACOG). Clinical Psychology & Psychotherapy. 2018. doi:10.1002/cpp.2345
10. Normann N, Morina N. The Efficacy of Metacognitive Therapy: A Systematic Review and Meta-Analysis. Frontiers in Psychology. 2018. doi:10.3389/fpsyg.2018.02211
